Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET
Company Participants
Justine Koenigsberg - Vice President, Investor Relations
Nello Mainolfi - Founder, President & CEO
Jared Gollob - Chief Medical Officer
Bruce Jacobs - Chief Financial Officer
Conference Call Participants
Eric Joseph - J.P. Morgan
Jeff Jones - Oppenheimer
Kelly Shi - Jefferies
Vikram Purohit - Morgan Stanley
Brad Canino - Stifel Nicolaus
Marc Frahm - TD Cowen
Kalpit Patel - B. Riley
Paul Jeng - Guggenheim
Jasmine Fels - UBS
Srikripa Devarakonda - Truist
Chris Shibutani - Goldman Sachs
Operator
Good day, and welcome to the Kymera Therapeutics Second Quarter 2024 Results Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Justine Koenigsberg, Head of Investor Relations. Please go ahead.
Justine Koenigsberg
Good morning, and welcome to Kymera's quarterly update call. Joining me this morning are Nello Mainolfi, President and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, our Chief Financial Officer. Following our prepared remarks, we will open the call to questions. In order to have enough time to address everyone's questions, please limit your questions to 1 and a relevant follow-up.
Before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call. With that, I'll now turn the call over to Nello.
Nello Mainolfi
Thank you, Justine, and good morning. Every day, we take important steps towards our goal of building a fully integrated global biotechnology company, demonstrating our ability to consistently deliver first and best-in-class programs that target validated pathways with the potential to address large underserved disease areas. The progress we've made over the past quarter highlights our novel approach to drug development that emphasizes innovative molecular design, fidelity of translation from preclinical settings to the clinic, data-driven development strategies and the commitment to maximize the impact of our signed to improve patients' lives.
Our unique approach has led to the development of a pipeline of exciting degrader medicines with the potential to change treatment paradigms for multiple diseases as evident in our recent updates and presentations at major medical congresses and publication in peer-review journals over the past few months. Our STAT6 program, for example, was featured at both ATS and DDW, MDM2 at ASCO and STAT3 at AACR and EHA. In addition, we published data from our noninterventional trial, evaluating IRAK4 expression in patients with HS in the Journal of Investigative Dermatology. The findings we've shared across these forums highlight the differentiated profile of our programs. Before handing the call over to Jared for a more detailed overview, I wanted to highlight 2 important updates in our immunology pipeline. I will start with our IRAK4 program. As a reminder, KT-474, IRAK4 degrader partnered with Sanofi, the first heterobifunctional molecule to have been dosed in healthy volunteers and then HS and AD patients. We have shown in our Phase I study TYK degradation of IRAK4 in blood and skin resulting in impact on biomarkers of inflammation, both systemically and in the skin of HS and AD patients. This robust PD profile has resulted in clinical benefits measured by EASI and pruritus scores in AD and HiSCR in pain in HS. KT-474, has likely been the most studied degrader in a Phase I setting.